Scholarlink

<p>Purpose: Benign prostatic hyperplasia (BPH) is common in elderly men, causing lower urinary tract symptoms (LUTSs). The 1470&#xa0;nm diode laser, with high vaporization efficiency and good hemostasis, is increasingly used for BPH. This study sought to comprehensively evaluate the efficacy and safety of 1470&#xa0;nm diode laser enucleation of the prostate (DiLEP) forBPH in a prospective, multicenter study. Methods: Conducted at two hospitals, BPH patients were randomized into two groups. Group A used a new 1470 nm diode laser device (Hefei Han’s Kereida), and Group B utilized a conventional and widely validated 1470 nm laser system (Wuhan Qizhi). Prostate volume (PV), maximum flow rate (Qmax), post-void residual (PVR), International Prostate Symptom Score (IPSS), and Quality of Life (QoL) score were measured pre- and post-operatively. Perioperative indices and complications were also recorded. Results: 143 patients (73 in Group A, 70 in Group B) completed follow-up. Baseline characteristics of two groups were comparable. Vital parameters remained within normal ranges following the surgical procedure. Both groups showed significant improvements in IPSS, QoL, Qmax, and PVR post-operatively, with no significant differences between groups. Complications occurred in 17 patients in Group A and 10 in Group B, all of which resolved spontaneously or were effectively managed with appropriate interventions. Conclusion: 1470 nm DiLEP is an effective and safe BPH treatment, relieving symptoms with few complications. The new device from Hefei Han’s Kereida performed reliably. This laser offers a valuable alternative to BPH surgeries.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The efficacy and safety of 1470 nm diode laser in the treatment of benign prostatic hyperplasia: a prospective, multicenter study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月23日

查看全文
  • Hao Xu,
  • Wenbo Kuang,
  • Dongxu Lin,
  • Kang Li,
  • Yang Luan,
  • Kai Cui,
  • Ting Yang,
  • Zhong Chen

摘要

Purpose: Benign prostatic hyperplasia (BPH) is common in elderly men, causing lower urinary tract symptoms (LUTSs). The 1470 nm diode laser, with high vaporization efficiency and good hemostasis, is increasingly used for BPH. This study sought to comprehensively evaluate the efficacy and safety of 1470 nm diode laser enucleation of the prostate (DiLEP) forBPH in a prospective, multicenter study. Methods: Conducted at two hospitals, BPH patients were randomized into two groups. Group A used a new 1470 nm diode laser device (Hefei Han’s Kereida), and Group B utilized a conventional and widely validated 1470 nm laser system (Wuhan Qizhi). Prostate volume (PV), maximum flow rate (Qmax), post-void residual (PVR), International Prostate Symptom Score (IPSS), and Quality of Life (QoL) score were measured pre- and post-operatively. Perioperative indices and complications were also recorded. Results: 143 patients (73 in Group A, 70 in Group B) completed follow-up. Baseline characteristics of two groups were comparable. Vital parameters remained within normal ranges following the surgical procedure. Both groups showed significant improvements in IPSS, QoL, Qmax, and PVR post-operatively, with no significant differences between groups. Complications occurred in 17 patients in Group A and 10 in Group B, all of which resolved spontaneously or were effectively managed with appropriate interventions. Conclusion: 1470 nm DiLEP is an effective and safe BPH treatment, relieving symptoms with few complications. The new device from Hefei Han’s Kereida performed reliably. This laser offers a valuable alternative to BPH surgeries.